KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Interest Expenses (2016 - 2017)

Historic Interest Expenses for Jazz Pharmaceuticals (JAZZ) over the last 5 years, with Q3 2013 value amounting to $614000.0.

  • Jazz Pharmaceuticals' Interest Expenses fell 4413.1% to $614000.0 in Q3 2013 from the same period last year, while for Jun 2014 it was $614000.0, marking a year-over-year decrease of 8233.6%. This contributed to the annual value of $1.7 million for FY2013, which is 5312.15% down from last year.
  • Jazz Pharmaceuticals' Interest Expenses amounted to $614000.0 in Q3 2013, which was down 4413.1% from $385000.0 recorded in Q2 2013.
  • Jazz Pharmaceuticals' Interest Expenses' 5-year high stood at $5.9 million during Q2 2009, with a 5-year trough of -$11.7 million in Q4 2010.
  • In the last 5 years, Jazz Pharmaceuticals' Interest Expenses had a median value of $1.1 million in 2012 and averaged $1.5 million.
  • Its Interest Expenses has fluctuated over the past 5 years, first crashed by 30220.41% in 2010, then surged by 6041.67% in 2013.
  • Over the past 5 years, Jazz Pharmaceuticals' Interest Expenses (Quarter) stood at $5.8 million in 2009, then crashed by 302.2% to -$11.7 million in 2010, then skyrocketed by 105.66% to $659000.0 in 2011, then skyrocketed by 243.4% to $2.3 million in 2012, then crashed by 72.87% to $614000.0 in 2013.
  • Its Interest Expenses was $614000.0 in Q3 2013, compared to $385000.0 in Q2 2013 and -$271000.0 in Q1 2013.